Journal article icon

Journal article

Biomarkers for severe eosinophilic asthma.

Abstract:

The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available ev...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.jaci.2017.10.005

Authors


Expand authors...
GlaxoSmithKline More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Journal of Allergy and Clinical Immunology Journal website
Volume:
140
Issue:
6
Pages:
1509-1518
Publication date:
2017-12-01
Acceptance date:
2017-10-17
DOI:
EISSN:
1097-6825
ISSN:
0091-6749
Pmid:
29221581
Source identifiers:
809785

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP